View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 11, 2011

Alkermes Reports ALKS 33 Phase II Results

Alkermes has released the results of a Phase II trial designed to assess the safety and efficacy of daily oral administration of ALKS 33 in patients with binge eating disorder. The randomised, double-blind and placebo-controlled study involved 68 patients. It demonstrated that ALKS 3

By cms admin

Alkermes has released the results of a Phase II trial designed to assess the safety and efficacy of daily oral administration of ALKS 33 in patients with binge eating disorder.

The randomised, double-blind and placebo-controlled study involved 68 patients. It demonstrated that ALKS 33 reduced the efficacy endpoint of self-reported weekly binge eating episodes from baseline.

The results were not significantly different from that observed with placebo, and hence Alkermes has determined not to pursue further development of ALKS 33 in this treatment area.

ALKS 33 is currently being evaluated as a treatment for alcohol dependence and, in combination with buprenorphine as ALKS 5461, for cocaine addiction and treatment-resistant depression.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology